Insider Trading June 17, 2026 06:13 PM

Samsara Director Jonathan Chadwick Offloads $334,723 in Class A Shares

Insider sale executed under a 10b5-1 plan coincides with analyst upgrades and strong Q1 fiscal 2027 results.

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
IOT

Samsara Inc. (NASDAQ:IOT) director Jonathan Chadwick executed a series of stock sales totaling approximately $334,723 on June 15, 2026. The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established in September 2025. This move follows recent positive earnings reports and multiple analyst price target adjustments, highlighting continued institutional interest in the IoT and industrial automation sector.

Samsara Director Jonathan Chadwick Offloads $334,723 in Class A Shares
IOT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Insider Activity: Director Jonathan Chadwick sold 10,000 shares at prices ranging from $33.03 to $34.34, executing a premium sale relative to the current $31.60 market price.
  • Financial Performance: Samsara reported strong Q1 fiscal 2027 results, with EPS of $0.17 beating estimates and revenue reaching $478.8 million, driving multiple analyst upgrades.
  • Market Impact: The IoT and industrial automation sector sees continued institutional interest, with major firms like RBC Capital and Piper Sandler raising price targets based on recurring revenue growth.

Jonathan Chadwick, serving as a director at Samsara Inc. (NASDAQ:IOT), has executed a significant reduction in his equity holdings within the company. On June 15, 2026, Chadwick sold a total of 10,000 shares of Samsara’s Class A Common Stock. The aggregate value of these transactions was approximately $334,723. These sales were facilitated through a pre-arranged Rule 10b5-1 trading plan, which Chadwick originally adopted on September 25, 2025. The use of this automated trading framework is a standard mechanism for executives and directors to manage equity liquidity while adhering to regulatory compliance standards.

The divestment was structured across two distinct blocks of shares, each executed at varying price points. The first block comprised 9,500 shares, which were sold at a weighted-average price of $33.4332 per share. These specific transactions occurred at prices ranging between $33.03 and $34.02. The second block consisted of 500 shares, sold at a weighted-average price of $34.216 per share, with individual transaction prices falling between $34.15 and $34.34. Notably, the prices at which these shares were sold represent a premium to Samsara’s current market valuation. At the time of the reporting, the stock was trading at $31.60, reflecting a decline of approximately 17% over the preceding year. Despite this recent downward trajectory, Samsara maintains a "GOOD" financial health score according to InvestingPro analysis. The company also boasts a robust gross profit margin of 76.3%, suggesting strong underlying operational efficiency despite the stock price depreciation.

Following the completion of these transactions, Chadwick’s direct holdings in Class A Common Stock stand at 43,865 shares. This figure encompasses certain restricted stock units (RSUs), which confer a contingent right to receive one share of Class A Common Stock upon vesting. Furthermore, Chadwick maintains an indirect position of 261,085 shares held through the CR Family Trust. The reported holdings also account for a prior transfer of 10,000 shares of Class A Common Stock from the CR Family Trust to Chadwick personally.

These insider transactions occur against a backdrop of heightened analyst activity and strong fundamental performance for Samsara. The company recently reported first-quarter fiscal 2027 earnings that exceeded market expectations. Earnings per share (EPS) reached $0.17, surpassing the forecasted $0.13. Revenue also outpaced projections, reaching $478.8 million against an expected $455.2 million. This positive financial momentum has prompted several major financial institutions to adjust their outlooks. RBC Capital raised its price target for Samsara to $42, citing 30% annual recurring revenue growth and sustained momentum with large enterprise customers. Piper Sandler also increased its price target to $40, reflecting positive results and raised guidance, despite noting lighter gross profit margins attributable to strategic investments. Additionally, Wolfe Research reiterated an Outperform rating with a $50 price target, highlighting confidence in the company’s growth pipeline while acknowledging challenges following its largest deal ever with First Student in fiscal 2026.

The intersection of insider selling and analyst upgrades presents a complex dynamic for investors. While the stock price has declined roughly 17% over the past year, the underlying business continues to demonstrate strong revenue growth and profitability metrics. The premium at which Chadwick’s shares were sold relative to the current market price may indicate a perceived valuation ceiling in the short term. Conversely, the sustained analyst confidence and strong fiscal performance suggest long-term operational strength.

Risks

  • Valuation Discrepancy: The stock has declined roughly 17% over the past year, and InvestingPro analysis suggests the stock may be overvalued relative to its Fair Value, despite a "GOOD" financial health score.
  • Margin Pressure: Piper Sandler noted lighter gross profit margins resulting from strategic investments, which could impact near-term profitability metrics.
  • Execution Challenges: Wolfe Research highlighted challenges following Samsara’s largest deal ever with First Student in fiscal 2026, indicating potential operational or integration risks in large-scale contracts.

More from Insider Trading

Oncotelic Therapeutics CEO Vuong Acquires Additional Shares Amid Stock Decline Jun 17, 2026 GitLab Director Sytse Sijbrandij Offloads $3.3M in Stock Amid Market Volatility Jun 17, 2026 Anterix Legal Executive Offloads $1.44M in Shares Amid Post-Earnings Rally Jun 17, 2026 Insider Activity: Bechtolsheim Divests $43M in Arista Networks Amid Strong Analyst Sentiment Jun 17, 2026 Nektar Therapeutics Executive Liquidation Aligns with Pre-Arranged Trading Protocol Jun 17, 2026